Tissue Engineered Skin Substitutes are innovative biomedical constructs designed to mimic the structure and function of natural skin, providing a therapeutic solution for burn victims, chronic wound patients, and individuals with skin disorders. These substitutes typically consist of a scaffold, often made of biocompatible materials, and cellular components such as fibroblasts and keratinocytes. The scaffold serves as a framework for cell attachment, proliferation, and tissue regeneration. Tissue-engineered skin substitutes aim to promote wound healing, reduce scarring, and restore skin integrity. They have the potential to overcome limitations associated with traditional skin grafts and donor site morbidity. In addition to their structural role, these substitutes can release growth factors and signaling molecules to accelerate tissue repair. Researchers continually refine the composition and design of tissue-engineered skin to enhance its biomechanical properties and promote optimal integration with the host tissue. The development of vascularized skin substitutes is a particular focus, addressing the challenge of adequate blood supply for graft survival. While tissue-engineered skin substitutes have made significant strides in regenerative medicine, ongoing research seeks to optimize their clinical efficacy, expand their applications, and improve their long-term outcomes for a diverse range of patients.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States